May 29, 2020
Menlo Therapeutics Receives FDA Approval of ZILXI(TM) (minocycline) topical foam, 1.5%, the First Topical Minocycline Treatment for Rosacea
Feb 18, 2020
Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea
Feb 06, 2020
Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for the Treatment of Papulopustular Rosacea in Journal of the American Academy of Dermatology
Jan 14, 2020
Foamix Announces AMZEEQ(TM) (minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S.
Jan 09, 2020
Foamix Announces AMZEEQ(TM) (minocycline) Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne
Dec 06, 2019
Global Acne Drugs (Salicylic acid, Retin-A Micro, Onexton, and Solodyn) Market Report 2020
Nov 04, 2019
Foamix Announces Publication of AMZEEQ(TM) (minocycline) Topical Foam Long Term Safety Data for Treatment Up to 1 Year in Journal of Clinical and Aesthetic Dermatology
Oct 18, 2019
Foamix Receives FDA Approval of AMZEEQ(TM) Topical Minocycline Treatment for Millions of Moderate to Severe Acne Sufferers
Oct 17, 2019
Foamix Announces FDA Acceptance of its New Drug Application for FMX103 Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea
Oct 10, 2019
Foamix to Present Data on its Topical Product Candidates for Acne, Rosacea at 39th Annual Fall Clinical Dermatology Conference
Oct 03, 2019
Citius Provides Update on Activities From IDWeek 2019
Jul 30, 2019
Citius Provides Developmental Plans for Mino-Wrap
Jun 25, 2019
BioPharmX Announces Positive Topline Results from Phase 2b Trial of BPX-04 for Papulopustular Rosacea
Jun 19, 2019
Global Acne Market Spotlight 2017-2018 & 2019-2026 - ResearchAndMarkets.com
May 22, 2019
BioPharmX Announces Last Patient Visit in Phase 2b Trial of BPX-04 for Papulopustular Rosacea
Mar 04, 2019
BioPharmX Completes Enrollment in Phase 2b Trial of BPX-04 for Patients with Papulopustular Rosacea
Jan 25, 2019
Citius Pharmaceuticals to Present at NobleCon15 Investor Conference
Oct 12, 2018
The Menarini Group Announces Commercial Agreement for Vabomere, Orbactiv and Minocin in 68 Countries
Oct 11, 2018
BioPharmX Initiates Phase 2b Trial of BPX-04 for Rosacea
Oct 02, 2018
The revenue of the dermatological drugs market in 2017